Barbie Autistic Toy Sparks Controversy: Mattel Faces Lawsuit
- l'essentiel La nouvelle poupée Barbie de Mattel,représentant une personne autiste,suscite des réactions contrastées.
- Le 12 janvier 2026, le géant du jouet Mattel a annoncé la mise en vente d'une nouvelle poupée Barbie censée représenter une personne atteinte de troubles du spectre autistique.Cette...
- Malgré un travail mené en collaboration avec une association luttant pour une meilleure représentation des personnes autistes dans les médias, cette nouvelle poupée Barbie n'a pas fait l'unanimité.
La nouvelle poupée Barbie de Mattel,représentant une personne autiste,suscite des réactions contrastées. Conçue avec des associations, elle vise à refléter la neurodiversité. Pourtant, certaines critiques dénoncent une approche marketing simpliste.
Le 12 janvier 2026, le géant du jouet Mattel a annoncé la mise en vente d’une nouvelle poupée Barbie censée représenter une personne atteinte de troubles du spectre autistique.Cette nouveauté s’inscrit dans la stratégie plus large de la marque américaine visant à élargir la diversité de ses modèles, après des poupées représentant notamment des personnes aveugles, atteintes de diabète, de vitiligo ou de trisomie 21.
Malgré un travail mené en collaboration avec une association luttant pour une meilleure représentation des personnes autistes dans les médias, cette nouvelle poupée Barbie n’a pas fait l’unanimité. À commencer par l’association SOS Autisme France, qui a annoncé vouloir porter plainte contre Mattel. Décryptons cette affaire.
Un travail de co-création mais une représentation discutée
Table of Contents
Mattel assure avoir conçu ce modèle en collaboration avec le “`html
The Inflation Reduction Act and Prescription Drug Pricing
The Inflation Reduction Act (IRA), signed into law on August 16, 2022, allows Medicare to negotiate prices for certain high-cost prescription drugs,aiming to lower healthcare costs for seniors and taxpayers.
Prior to the IRA, medicare was largely prohibited from directly negotiating drug prices with pharmaceutical companies.This limitation contributed to considerably higher drug costs in the United States compared to other developed nations. The IRA addresses this by enabling the centers for Medicare & Medicaid Services (CMS) to select drugs for negotiation based on factors like high Medicare spending and lack of generic or biosimilar competition.
Such as, in August 2023, HHS announced the first 10 drugs selected for negotiation, including Eliquis (apixaban) for preventing blood clots, Jardiance (empagliflozin) for diabetes, and Xarelto (rivaroxaban) for preventing blood clots. Negotiated prices are expected to take effect in 2026.
how medicare Drug Price Negotiation Works
Medicare drug price negotiation under the IRA is a phased-in process, starting with a small number of drugs and expanding over time.
The process involves CMS identifying eligible drugs – those without generic or biosimilar competition and meeting specific spending thresholds. CMS then engages in negotiations with the drug manufacturers. if an agreement isn’t reached, a manufacturer can face a significant excise tax or withdraw from Medicare and Medicaid. The negotiated prices apply to Medicare Part D and Medicare Part B.
According to the Congressional Budget Office (CBO), the IRA is projected to reduce federal deficits by $264 billion over ten years, largely due to the savings from drug price negotiation. The CBO estimates that Medicare spending on drugs will decrease by $98.1 billion between 2027 and 2031.
Drugs Eligible for Negotiation
The IRA specifies criteria for drugs eligible for negotiation, focusing on those with the highest Medicare spending and limited competition.
Initially, the law allows for negotiation of 10 drugs in 2026, increasing to 15 drugs in 2027, 20 drugs in 2028, and 25 drugs in 2029 and beyond. Drugs are excluded from negotiation if they have generic or biosimilar competition, are protected by orphan drug exclusivity, or have low Medicare spending. The Food and Drug Administration (FDA) plays a role in determining eligibility based on these criteria.
As of December 2023, the 10 drugs selected for the first round of negotiations represent $50.5 billion in Medicare Part D and Part B spending during the 2022 calendar year,according to CMS. These drugs treat conditions such as diabetes, heart failure, and blood clots.
Impact on Pharmaceutical Companies
The IRA’s drug price negotiation provisions have drawn significant opposition from the pharmaceutical industry, which argues that they will stifle innovation.
Industry groups, such as the Pharmaceutical Research and Manufacturers of America (PhRMA), have filed lawsuits challenging the constitutionality of the law. They contend that the negotiation process amounts to a taking of intellectual property without just compensation, violating the Fifth Amendment. As of January 15, 2026, these legal challenges are ongoing, with rulings expected from various federal courts.
In response to the IRA, some pharmaceutical companies have announced plans to accelerate drug progress and launch new products before they become eligible for negotiation. as an example, Merck & Co. stated it would prioritize launching new drugs to avoid price controls.
Future of Drug Pricing Reform
The IRA represents a significant step towards lowering prescription drug costs, but further reforms are being considered.
Potential future changes include expanding the number of drugs eligible for negotiation, addressing drug prices in Medicare part D’s coverage gap (the “donut hole”), and allowing the importation of drugs from other countries. The Biden Administration has expressed support for these additional measures. Legislative proposals are being debated in Congress to build on the IRA